Feb. 22, 2024
by Andrii Buvailo, PhD
News
In a collaborative effort, Zapata Computing (Zapata AI), together with Insilico Medicine, the University of Toronto, and St. Jude Children's …
Feb. 21, 2024
by BiopharmaTrend
News
Insilico Medicine, a leader in AI-driven drug discovery, has developed a new preclinical candidate, ISM9682, aimed at treating advanced solid …
Feb. 19, 2024
by Andrii Buvailo, PhD
Biopharma insight
Sponsored by RECEPTOR.AI
Receptor.AI, a London-based drug discovery company and NVIDIA Inception member, has successfully integrated NVIDIA BioNeMo cloud APIs with their end-to-end …
Feb. 6, 2024
by Andrii Buvailo, PhD
Interview
As we stand at the crossroads of artificial intelligence (AI) and biotech, what future awaits protein design, and how are …
Jan. 26, 2024
by Natalia Honchar
Biopharma insight
When we hear “AI in drug discovery”, there is a high chance our imagination would draw a small molecule discovery …
Jan. 23, 2024
by Andrii Buvailo
Interview
The development of oncology drugs faces significant challenges, including a high failure rate (97%) in clinical trials, due to complex …
We at Receptor.AI are excited to present the next important milestone in the development of our next-generation AI docking model, …
Jan. 12, 2024
by Andrii Buvailo
News
Verge Genomics, a clinical-stage biotechnology company, has just initiated a Phase 1b proof-of-concept study for VRG50635, a drug developed for …
Jan. 10, 2024
by Emma Banks
Biopharma insight
As we step into 2024, the global life science industry finds itself at a crossroads, facing plenty of challenges alongside …
Jan. 3, 2024
by Dana Sokolova
News
Executives from the French AI drug discovery company Owkin have embarked on a new venture, launching Bioptimus, a startup dedicated …